Nom du produit:1-(oxan-2-yl)-1H-pyrazole
IUPAC Name:1-(oxan-2-yl)-1H-pyrazole
- CAS:449758-17-2
- Formule moléculaire:C8H12N2O
- Pureté:98%+
- Numéro de catalogue:CM104631
- Poids moléculaire:152.2
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:449758-17-2
- Formule moléculaire:C8H12N2O
- Point de fusion:-
- Code SMILES:C1CCC(OC1)N1C=CC=N1
- Densité:
- Numéro de catalogue:CM104631
- Poids moléculaire:152.2
- Point d'ébullition:269.7°C at 760 mmHg
- N° Mdl:MFCD11044692
- Stockage:2-8°C
Category Infos
- Pyrazoles
- Pyrazoles are organic compounds of the general formula C3H3N2H. It is a five-membered heterocycle consisting of three carbon atoms and two adjacent nitrogen atoms. As an H-bond-donating heterocycle, pyrazole has been used as a more lipophilic and metabolically more stable bioisomer of phenol. Pyrazoles have attracted more and more attention due to their broad spectrum of action and strong efficacy.
- Pyrazone
- Custom pyrazone for customers from all over the world are our main business.
- Tetrahydropyrans
- Tetrahydropyran is an organic compound consisting of a saturated six-membered ring containing five carbon atoms and one oxygen atom. Tetrahydropyrans are common structural motifs in natural products and synthetic therapeutic molecules. In nature, these six-membered oxygen heterocycles are usually assembled by intramolecular reactions, including oxygen Michael addition or ring opening of epoxy alcohols. In fact, polyether natural products have been particularly extensively studied for their fascinating structures and important biological properties; these are often formed through endoselective epoxy open cascades.
Column Infos
- Pyrans
- Pyrans are an important class of six-membered heterocyclic compounds, non-aromatic rings, composed of five carbon atoms and one oxygen atom, and contain two double bonds. The molecular formula of pyran is C5H6O, and there are two isomers. Pyrans, together with benzo derivatives, form scaffolds for a variety of drug applications, many of which are approved and promising candidates in clinical trials and recently isolated bioactive natural products.
- Asciminib
- Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile. Scemblix now approved for newly diagnosed and previously treated CML, allowing four times the patients access to potential new standard of care.
Scemblix is an orally available tyrosine kinase inhibitor that works by blocking the BCR-ABL1 fusion protein, a known hallmark of certain leukemias. The drug was first approved for CML three years ago, winning two indications. The first is for the treatment of Philadelphia chromosome-positive, chronic phase CML, for which the drug was given accelerated approval. The second is a full approval for the same patient population, with the additional specification that they carry the T315I mutation.